Imagine this: a safe, effective birth control method that puts the power directly in your hands, yet it's surprisingly underutilized in the U.S. That's the reality of self-administered injectable contraception, a method that deserves far more attention than it currently receives. A recent study reveals a significant gap in its adoption, despite its potential to empower individuals with reproductive choices.
This groundbreaking research, published in the journal Obstetrics & Gynecology, sheds light on the barriers hindering the widespread use of this option. The study found that only about a quarter of reproductive health experts prescribe it, and many are even unaware of its availability.
"Since most physicians don't know that this is an option, patients don’t know about it,” explains Dr. Jennifer Karlin, a UCSF associate professor and the study's senior author. "It’s safe, effective, and puts the control in patients’ own hands. We should be talking about and offering it to patients without biases.”
The research surveyed 422 clinicians who regularly prescribe birth control. Astonishingly, only about a third of those familiar with the self-administered option actually prescribe it. The reasons cited for not prescribing it were varied, including concerns about patients' ability to self-inject, medication availability at pharmacies, and a lack of standardized patient counseling and prescription protocols.
So, what exactly is this method? It involves depot medroxyprogesterone acetate (DMPA), a synthetic form of the hormone progestin, delivered via injection. This injection prevents pregnancy for up to three months by preventing ovulation, thickening cervical mucus, and thinning the uterine lining.
There are two forms of DMPA: an intramuscular injection (Depo-Provera), which must be administered by a healthcare provider, and a subcutaneous version, which is injected just under the skin. The subcutaneous version is designed for self-injection, much like the increasingly popular GLP-1 weight-loss drugs.
But here's where it gets controversial... the drug has been linked to potential side effects, such as reduced bone mineral density, weight gain, and a rare benign brain tumor called meningioma. While the overall risk is low, it's crucial for clinicians to discuss these risks and benefits with their patients.
The subcutaneous version, approved in 2004, is officially intended for clinician administration, yet physicians have been training patients in self-injection for years. Interestingly, self-injectable contraception is more common globally, especially in sub-Saharan Africa. Its use increased in the U.S. during the COVID-19 pandemic, with over half of the prescribers surveyed learning about it between 2020 and 2022.
Both international and national guidelines recommend making this option accessible to all patients. However, the study found that providers in states with restricted abortion access were less likely to prescribe it. Other obstacles include insufficient educational materials, lack of staff support, and limited time for patient consultations.
To boost accessibility, the authors suggest an education campaign for clinicians on self-administration of injectable contraceptives. They also advocate for FDA approval of the self-administered version, insurance coverage, and streamlined clinic workflows.
This study, supported by a grant from the Society of Family Planning, highlights a critical need for change.
What are your thoughts? Do you think this method should be more widely available? Are you surprised by the findings? Share your opinions in the comments below!
